Vifor Pharma (GNHAF) Stock Price, News & Analysis

Company Overview

Vifor Pharma AG is a Switzerland-based global specialty pharmaceutical company dedicated to the treatment of iron deficiency, nephrology and cardio-renal therapies. With a focus on patient-centric innovation, the company develops, manufactures and markets a portfolio of medicines that address critical unmet needs in chronic kidney disease, heart failure and other iron-related disorders.

The company’s core product offerings include intravenous iron therapies such as Venofer (iron sucrose) and Ferinject/Injectafer (ferric carboxymaltose), which are used to correct iron deficiency in a range of clinical settings. In addition, Vifor Pharma markets erythropoiesis-stimulating agents and biosimilars—such as Mircera (continuous erythropoietin receptor activator) and Retacrit (epoetin alfa)—to support the management of anemia in patients with chronic kidney disease. Beyond its marketed products, the company maintains an active pipeline in areas such as hepcidin modulation and next-generation iron formulations.

Headquartered in St. Gallen, Switzerland, Vifor Pharma operates through regional hubs in Europe, North America, Asia Pacific and Latin America. The company leverages a network of proprietary manufacturing facilities and strategic partnerships to ensure supply chain resilience and to accelerate global market access for its therapies. Vifor Pharma employs a multidisciplinary team of medical, regulatory and commercial experts to drive research, clinical development and product launches worldwide.

Over the past decade, Vifor Pharma has evolved through strategic collaborations and corporate restructuring. In 2020 it was listed on the SIX Swiss Exchange following a spin-off from its former parent company, marking a new chapter for the organization as an independent, publicly traded specialty pharmaceutical leader.

Key Stats

• Today's Range: $181.25 to $181.25
• 50-Day Range: $181.25 to $181.25
• 52-Week Range: $174.25 to $183.50
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GNHAF Stock Analysis - Frequently Asked Questions

How have GNHAF shares performed this year?

Vifor Pharma's stock was trading at $181.25 at the beginning of the year. Since then, GNHAF shares have increased by 0.0% and is now trading at $181.25.

How do I buy shares of Vifor Pharma?

Shares of GNHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GNHAF
• CIK: N/A
• Web: www.viforpharma.com
• Phone: (158) 851-8000
• Fax: N/A
• Employees: 2,200
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A